导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.07% | 3002/4773 |
| 近一周 | -1.32% | 1039/5458 |
| 近一月 | -1.30% | 1131/5421 |
| 近一季 | 0.80% | 842/5205 |
| 近半年 | -0.03% | 1386/4920 |
| 近一年 | 3.05% | 2167/4361 |
| 近两年 | 44.03% | 1748/2954 |
| 近三年 | 24.49% | 1318/2253 |
| 成立以来 | 14.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.99% 3995/4961 |
4.17% 2919/5312 |
- - |
- - |
| 2025 | 22.55% 1959/4813 |
-0.48% 2269/3635 |
2.53% 1508/4076 |
16.59% 2630/4524 |
3.01% 787/4813 |
| 2024 | 14.38% 1051/3463 |
2.59% 748/2808 |
-0.60% 795/3014 |
14.10% 2046/3129 |
-1.70% 1800/3463 |
| 2023 | -17.43% 1735/2656 |
-2.88% 2054/2280 |
-6.37% 1628/2385 |
-1.34% 506/2515 |
-7.96% 2225/2655 |
| 2022 | -22.92% 1098/2207 |
-9.28% 317/1919 |
4.68% 983/2016 |
-16.91% 1521/2113 |
-2.32% 1794/2208 |
| 2021 | -11.28% 1106/1822 |
-5.65% 944/1255 |
10.76% 438/1330 |
-11.09% 1255/1466 |
-4.52% 1487/1822 |
| 2020 | - - |
- - |
- - |
16.02% 177/1164 |
18.33% 96/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方上证50增强C VS. 长安沪深300非周期A(740101) |